The Technical Analyst
SIGA Technologies Inc [SIGA]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
SIGA Technologies Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.61% $8.28
America/New_York / 19 apr 2024 @ 14:27
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 588.64 mill |
| EPS: | 0.950 |
| P/E: | 8.72 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 71.09 mill |
| Avg Daily Volume: | 0.781 mill |
| RATING 2024-04-19 |
|---|
| S- |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 8.72 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.18x |
| Company: PE 8.72 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$22.14 (167.35%) $13.86 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 7.87 - 8.77 ( +/- 5.38%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-25 | Miller Larry R. | Buy | 61 347 | Stock Option (Right to buy) |
| 2024-03-25 | Miller Larry R. | Buy | 49 940 | Common Stock, par value $.0001 per share |
| 2024-03-25 | Miller Larry R. | Sell | 19 040 | Common Stock, par value $.0001 per share |
| 2024-03-25 | Miller Larry R. | Buy | 25 504 | Stock Option (Right to buy) |
| 2024-03-25 | Miller Larry R. | Buy | 20 761 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 83.65 |
| Last 94 transactions |
| Buy: 1 860 668 | Sell: 519 385 |
Forecast:
16:00 - $8.28
Live Trading Signals (every 1 min)
Forecast
1: 14:36 - $8.28
Forecast 2: 15:26 - $8.32
Forecast 3: 16:00 - $8.28
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.28 (0.61% ) |
| Volume | 0.330 mill |
| Avg. Vol. | 0.781 mill |
| % of Avg. Vol | 42.17 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SIGA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $4.62 | N/A | Active |
|---|
SIGA
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
Latest Press Releases
2024-04-01 16:05:00 - Press Release
Siga Amends International Promotion Agreement With Meridian To Enhance International Growth Opportunities Of Oral Tpoxx®
New york, april 01, 2024 (globe newswire) -- siga technologies, inc. (nasdaq: siga), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that it entered into an amendment to its international promotion agreement with meridian medical technologies, inc. (meridian). effective june 1, siga will drive international promotion activities for oral tpoxx® while maintaining its contractual relationship with meridian to maintain continuity for key customer relationships.
2024-03-12 16:05:00 - Press Release
Siga Reports Financial Results For Three And Twelve Months Ended December 31, 2023
• increased product sales to $131 million in 2023 • grew pre-tax operating income to $84 million in 2023 • declared today a special cash dividend of $0.60 per share • corporate update conference call today at 4:30 pm et new york, march 12, 2024 (globe newswire) -- siga technologies, inc. (siga) (nasdaq: siga), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended december 31, 2023. “in 2023, siga had approximately $131 million in product revenues and approximately $84 million of pre-tax operating income,” stated diem nguyen, chief executive officer.
2024-03-12 07:30:00 - Press Release
Siga Declares Special Cash Dividend Of $0.60 Per Share
New york, march 12, 2024 (globe newswire) -- siga technologies, inc. (siga) (nasdaq: siga), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company's common stock. this represents an increase of $0.15 per share, or 33%, over the cash dividend paid in june 2023.
2024-03-05 07:30:00 - Press Release
Siga Technologies To Host Business Update Call On March 12th, 2024 Following Release Of Fourth Quarter And Full Year 2023 Financial Results
New york, march 05, 2024 (globe newswire) -- siga technologies, inc. (siga) (nasdaq: siga), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 p.m. et on tuesday, march 12th, 2024. participating in the call will be dr. diem nguyen, chief executive officer, and daniel luckshire, chief financial officer.
2024-01-22 07:30:00 - Press Release
Siga Announces Appointment Of Diem Nguyen, Ph.d., Mba, As New Chief Executive Officer
New york, jan. 22, 2024 (globe newswire) -- siga technologies, inc. (siga) (nasdaq: siga), a commercial-stage pharmaceutical company focused on the health security market, today announced that diem nguyen, ph.d., will join the company as chief executive officer (ceo), effective january 27, 2024, and will also be appointed to the company's board of directors. siga's current ceo, dr. phil gomez, will retire from siga on january 26, 2024.
Latest News
2024-04-15 18:56:16 - Zacks Investment Research
Siga Technologies Inc. (SIGA) Advances While Market Declines: Some Information for Investors
Siga Technologies Inc. (SIGA) reachead $8.88 at the closing of the latest trading day, reflecting a +0.79% change compared to its last close.
2024-04-12 11:01:21 - Zacks Investment Research
Best Momentum Stocks to Buy for April 12th
SIGA, SEIC and NTRS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 12, 2024.
2024-04-12 08:32:05 - Zacks Investment Research
New Strong Buy Stocks for April 12th
ZUO, INTZ, SIGA, ENVB and NTRS have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2024.
2024-04-12 07:36:03 - Zacks Investment Research
Best Value Stocks to Buy for April 12th
SIGA and AZZ made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 12, 2024.
2024-04-10 11:01:04 - Zacks Investment Research
Best Momentum Stocks to Buy for April 10th
DELL, AGRO and SIGA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 10, 2023.
2024-04-10 07:46:03 - Zacks Investment Research
New Strong Buy Stocks for April 10th
DELL, WEAV, AGRO, SIGA and STEP have been added to the Zacks Rank #1 (Strong Buy) List on April 10, 2023.
2024-04-02 11:01:06 - Zacks Investment Research
Best Momentum Stocks to Buy for April 2nd
HITI, MPC and SIGA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 2, 2023.
2024-04-02 08:06:04 - Zacks Investment Research
New Strong Buy Stocks for April 2nd
CXDO, HITI, SIGA, CPG and CTKB have been added to the Zacks Rank #1 (Strong Buy) List on April 2, 2023.
2024-03-25 14:46:18 - Seeking Alpha
Siga Technologies: Preparing For A Contingency If Tomorrow Comes
2024-03-21 13:01:07 - Zacks Investment Research
All You Need to Know About Siga Technologies (SIGA) Rating Upgrade to Buy
Siga Technologies (SIGA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.